Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This was a double-blind, randomised, placebo-controlled, parallel-group, multicentre,
multinational, Phase II study in 528 subjects with pain due to Fibromyalgia syndrome(FMS).
Subjects were randomised in a 1:1:1:1 ratio to receive placebo, Eslicarbazepine acetate (ESL)
400 mg once daily (QD), ESL 800 mg QD or ESL 1200 mg QD. The study was carried out as
follows.